Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time. The event will discuss top-line data from their PRIME Phase 1b clinical trial.
Participants can join via webcast or dial in using the toll-free number 888-506-0062 (US) or +1 973-528-0011 (International) with access code 289672. The company has made available both the original data announcement and the presentation materials on their website.
Details
News Market Reaction – REVB
On Sep 10, the first trading day after this news, REVB closed 6.01% above the previous close.
Data tracked by StockTitan Argus for the Sep 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.
A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.
For more information on Revelation, please visit https://www.revbiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.